Government-Owned Inventions; Availability for Licensing, 47629-47630 [2018-20484]

Download as PDF Federal Register / Vol. 83, No. 183 / Thursday, September 20, 2018 / Notices order to facilitate their entry into the building. Contact Ann Ferrero using the information mentioned above by Thursday, October 18, 2018, 12:00 p.m. ET. All attendees are required to present government-issued identification prior to entry. The meeting will also be accessible via webcast. Instructions on how to access the meeting via webcast will be provided upon registration. Amy P. McNulty, Acting Director, Division of the Executive Secretariat. [FR Doc. 2018–20428 Filed 9–19–18; 8:45 am] BILLING CODE 4165–15–P Dated: September 14, 2018. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health [FR Doc. 2018–20418 Filed 9–19–18; 8:45 am] National Cancer Institute; Notice of Meeting BILLING CODE 4140–01–P amozie on DSK3GDR082PROD with NOTICES1 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Institute Council of Research Advocates. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov). Name of Committee: National Cancer Institute Council of Research Advocates. Date: October 19, 2018. Time: 9:00 a.m. to 4:30 p.m. Agenda: Welcome and Chairman’s Remarks, NCI Updates, Legislative Update, Budget Update, and Director’s Update. Place: National Institutes of Health, 35A Convent Drive, Building 35A, 640, Bethesda, MD 20892. Contact Person: Amy Williams, NCI Office of Advocacy Relations, National Cancer Institute, NIH, 31 Center Drive, Building 31, Room 10A28, Bethesda, MD 20892, 240–781– 3360 williaam@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a VerDate Sep<11>2014 18:01 Sep 19, 2018 Jkt 244001 government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: NCRA: https:// deainfo.nci.nih.gov/advisory/ncra/ncra.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Barry Buchbinder, Ph.D., 240–627– 3678; barry.buchbinder@nih.gov. Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. SUMMARY: Glycan-Masked Engineered Outer Domains of HIV-1 GP120 and Their Use Description of Technology: PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 47629 The VRC01-class of potent, broadly neutralizing antibodies (bnAbs) targets the conserved CD4-binding site (CD4bs) of HIV-1 Env which has been a major target of HIV-vaccine design. The current best priming immunogen to engage the VRC01-class germline precursors is the eOD-GT8 60mer, which elicits VRC01-class precursors in multiple transgenic mouse models. However, a large proportion of the antibodies elicited by eOD-GT8 60mer are non-CD4bs or ‘‘off-target’’ antibodies, undermining its effectiveness in eliciting the VRC01class bnAb precursors. Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases introduced multiple N-linked glycosylation sites to mask non-CD4bs regions of eOD-GT8 60mer to focus the antibody immune response to the CD4bs. Several glycan-masked mutants showed significantly decreased antibody binding to non-CD4bs ‘‘offtarget’’ epitopes while maintaining strong binding to CD4bs-specific bnAbs. Furthermore, in vivo studies showed that immunization with the best glycanmasked eOD-GT8 mutants resulted in significant increases in the elicitation of CD4bs-specific serum antibodies, CD4bs-specific B cells in the spleen, and VRC01-class precursors, compared to immunization with the parental eODGT8 immunogen. In conclusion, because of their improved antigenic and immunogenic profiles, glycan-masked eOD-GT8 60mer mutants may serve as improved priming immunogens to elicit VRC01-class bnAbs in humans. Potential Commercial Applications: • HIV-1 vaccine—the priming component in a prime-boost approach. Competitive Advantages: • Reduced off-target immunogenicity. • Improved efficacy in eliciting precursors for broadly neutralizing CD4bs antibodies. • Facilitates the development of VRC01-class bnAbs in humans. Development Stage: In vivo testing (rodents). Inventors: John R. Mascola (NIAID), Hongying Duan (NIAID), Xuejun Chen (NIAID), Cheng Cheng (NIAID) and Jeffrey C. Boyington (NIAID). Publications: Duan, H. et al., Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. Immunity 49, 301 (2018). Intellectual Property: HHS Reference Number E–083–2017 includes U.S. Provisional Patent Application Number 62/476,397 filed 03/24/2017 and PCT E:\FR\FM\20SEN1.SGM 20SEN1 47630 Federal Register / Vol. 83, No. 183 / Thursday, September 20, 2018 / Notices Application Number PCT/US2018/ 024330 filed 03/26/2018. Licensing Contact: Barry Buchbinder, Ph.D., 240–627–3678; barry.buchbinder@nih.gov. amozie on DSK3GDR082PROD with NOTICES1 Dated: September 10, 2018. Suzanne M. Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. 672, Bethesda, MD 20892, zhanggu@ mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS) Dated: September 14, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–20484 Filed 9–19–18; 8:45 am] [FR Doc. 2018–20424 Filed 9–19–18; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health National Institute of Dental & Craniofacial Research; Notice of Closed Meetings National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; DPBRN ARC. Date: November 14, 2018. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Garden Inn, 7301 Waverly Street, Bethesda, MD 20814. Contact Person: Guo He Zhang, MPH, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, 6701 Democracy Boulevard, Suite 672, Bethesda, MD 20892, zhanggu@ mail.nih.gov. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; DPBRN Coordinating Center. Date: November 14, 2018. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, Bethesda, MD 20814. Contact Person: Guo He Zhang, MPH, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, 6701 Democracy Boulevard, Suite Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel Centers of Excellence for Translational Research (CETR) (U19). Date: October 11–12, 2018. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Yong Gao, Ph.D., Scientific Review Officer Scientific Review Program, Division of Extramural Activities, Room #3G13B, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Rockville, MD 20892–7616, (240) 669–5048, yong.gao@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) VerDate Sep<11>2014 18:01 Sep 19, 2018 Jkt 244001 Dated: September 14, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–20421 Filed 9–19–18; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Molecular Genetics B Study Section, September 27, 2018, 10:00 a.m. to September 28, 2018, 06:00 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the Federal Register on September 06, 2018, 83FR173 pg. 45264. The meeting will be held on September 27, 2018, starting at 8:30 a.m. The meeting location remains the same. The meeting is closed to the public. Dated: September 14, 2018. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–20415 Filed 9–19–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Clinical Neuroscience and Neurodegeneration Study Section. Date: October 3–4, 2018. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Alessandra C. Rovescalli, Ph.D., Scientific Review Officer, National Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, Rm 5205 MSC7846, Bethesda, MD 20892, (301) 435– 1021, rovescaa@mail.nih.gov. E:\FR\FM\20SEN1.SGM 20SEN1

Agencies

[Federal Register Volume 83, Number 183 (Thursday, September 20, 2018)]
[Notices]
[Pages 47629-47630]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-20484]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Barry Buchbinder, Ph.D., 240-627-3678; 
[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: 
    Technology description follows.

Glycan-Masked Engineered Outer Domains of HIV-1 GP120 and Their Use

    Description of Technology:
    The VRC01-class of potent, broadly neutralizing antibodies (bnAbs) 
targets the conserved CD4-binding site (CD4bs) of HIV-1 Env which has 
been a major target of HIV-vaccine design. The current best priming 
immunogen to engage the VRC01-class germline precursors is the eOD-GT8 
60mer, which elicits VRC01-class precursors in multiple transgenic 
mouse models. However, a large proportion of the antibodies elicited by 
eOD-GT8 60mer are non-CD4bs or ``off-target'' antibodies, undermining 
its effectiveness in eliciting the VRC01-class bnAb precursors.
    Researchers at the Vaccine Research Center (VRC) of the National 
Institute of Allergy and Infectious Diseases introduced multiple N-
linked glycosylation sites to mask non-CD4bs regions of eOD-GT8 60mer 
to focus the antibody immune response to the CD4bs.
    Several glycan-masked mutants showed significantly decreased 
antibody binding to non-CD4bs ``off-target'' epitopes while maintaining 
strong binding to CD4bs-specific bnAbs. Furthermore, in vivo studies 
showed that immunization with the best glycan-masked eOD-GT8 mutants 
resulted in significant increases in the elicitation of CD4bs-specific 
serum antibodies, CD4bs-specific B cells in the spleen, and VRC01-class 
precursors, compared to immunization with the parental eOD-GT8 
immunogen. In conclusion, because of their improved antigenic and 
immunogenic profiles, glycan-masked eOD-GT8 60mer mutants may serve as 
improved priming immunogens to elicit VRC01-class bnAbs in humans.
    Potential Commercial Applications:
     HIV-1 vaccine--the priming component in a prime-boost 
approach.
    Competitive Advantages:
     Reduced off-target immunogenicity.
     Improved efficacy in eliciting precursors for broadly 
neutralizing CD4bs antibodies.
     Facilitates the development of VRC01-class bnAbs in 
humans.
    Development Stage: In vivo testing (rodents).
    Inventors: John R. Mascola (NIAID), Hongying Duan (NIAID), Xuejun 
Chen (NIAID), Cheng Cheng (NIAID) and Jeffrey C. Boyington (NIAID).
    Publications: Duan, H. et al., Glycan Masking Focuses Immune 
Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of 
VRC01-Class Precursor Antibodies. Immunity 49, 301 (2018).
    Intellectual Property: HHS Reference Number E-083-2017 includes 
U.S. Provisional Patent Application Number 62/476,397 filed 03/24/2017 
and PCT

[[Page 47630]]

Application Number PCT/US2018/024330 filed 03/26/2018.
    Licensing Contact: Barry Buchbinder, Ph.D., 240-627-3678; 
[email protected].

    Dated: September 10, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-20484 Filed 9-19-18; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.